Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia
Amount Raised
$75 Million
Round Type
Series B
ConcordPharmaceutical ManufacturingInvestors
Description
Comanche Biopharma Corp. announced the closing of an oversubscribed $75 million Series B financing to advance its mission to develop and make globally available the first treatment targeting a root cause of preeclampsia.
Quick answer
Comanche Biopharma raised $75 Million in a Series B round, dated January 18, 2024. Investors: Lilly Asia Ventures, New Enterprise Associates, GV, Atlas Venture, Longview Healthcare Ventures and F Prime Capital. Comanche Biopharma is based in Concord, Massachusetts, United States.
- How much did Comanche Biopharma raise?
- Comanche Biopharma raised $75 Million in a Series B round on January 18, 2024.
- Who invested in Comanche Biopharma?
- Lilly Asia Ventures, New Enterprise Associates, GV, Atlas Venture, Longview Healthcare Ventures and F Prime Capital are named as investors in this round.
- What does Comanche Biopharma do?
- Comanche is a biopharmaceutical company developing novel siRNA molecules for the treatment of preeclampsia.
- Where is Comanche Biopharma based and how big is it?
- Comanche Biopharma is based in Concord, Massachusetts, United States.
- Who are the decision-makers at Comanche Biopharma?
- Fundz holds 1 contact at Comanche Biopharma. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Pharmaceutical Manufacturing around the same time
Companies in the same sectors as Comanche Biopharma that raised within 45 days of this round, from Fundz verified event records.
- Zeno Health raised $25M (Series C) on February 27, 2024.
- XORTX Therapeutics raised $2.5M (Seed) on February 19, 2024.
- COUR Pharmaceuticals raised $105M (Funding Round) on February 11, 2024.
- DUDE CHEM raised $6.5M (Funding Round) on February 7, 2024.
- Orexa raised $940K (Seed) on February 2, 2024.
- COUR Pharmaceuticals raised $105M (Series A) on January 30, 2024.
Who to call at Comanche Biopharma, and when
A new round usually means Comanche Biopharma is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Comanche Biopharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Comanche Biopharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Comanche Biopharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Comanche Biopharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansComanche Biopharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.